Print A federal judge has agreed to Illumina’s request to hold an injunction hearing in San Diego rather than Washington, D.C., as the Federal Trade Commission moves to temporarily prevent the sequencing giant from acquiring cancer diagnostic firm Grail. It’s the latest development in an ongoing feud between Illumina and the FTC. The FTC argues that the San Diego company’s $7.1 billion bid to buy Grail would prevent other companies from launching their own early detection cancer tests. Illumina denies that claim, adding that it has the expertise needed to help Grail get its diagnostic test ready for primetime.